Dr. Shtern is a founding member of AdMeTech’s Board of Directors, and she has served as President and CEO since December 1, 1997. The Founding Board presented Dr. Shtern with the challenge of ensuring that AdMeTech Foundation fulfill its mission – to provide unique and critically needed international leadership for expediting the development and implementation of advanced diagnostic tools for improved prevention, early detection and treatment of prostate cancer.
Dr. Albala graduated from Lafayette College and Michigan State University College of Human Medicine and completed his residency at Dartmouth. After an endourology fellowship at Washington University, he served as a Professor in Urology and Radiology at Loyola University Chicago. Dr. Albala was a Professor at Duke University, where he was Director for the Center of Minimally Invasive and Robotic Urological Surgery. Dr. Albala was also a White House Fellow advising on public health related issues. He has 150+ publications in peer-reviewed journals and has authored four textbooks. He serves on the editorial boards and/or as reviewer for 10+ journals.
Dr. Andriole received his MD from Jefferson Medical College and completed his post-doctoral education at the University of Rochester (surgery residency) and Brigham and Women’s Hospital (urology residency), and was a fellow at the National Cancer Institute. He is board-certified in Urology and specializes in urologic surgery (including urologic cancer surgery) and prostate cancer.
Dr. Babayan graduated from Indiana University School of Medicine and did his surgical training at Yale-New Haven Hospital before a urology residency at Boston University Medical Center. He was an AUA Research Scholar performing research in the field of hyperthermia. Dr. Babayan is a founding member of the Endourological Society and is a past president of the American Urological Association. His clinical interests center around minimally-invasive therapies in the field of urology, BPH, prostate cancer and urologic oncology, endourology, and he is currently one of four urologic surgeons at BMC using the daVinci Robot for robotic assisted laparoscopic radical prostatectomy.
Dr. Barentsz is Founding Member and Past-President of the ICIS and Past-President of the ESUR. He has 200+ peer reviewed publications: his most important contributions include rebirth of the macrophages specific nano-MR contrast agent (Combidex ®); development, validation and implementation of multi-parametric MRI, resulting in the wide-spread use of prostate MRI; and development plus implementation of the PI-RADS scoring system for structured interpretation of prostate MRI’s. Dr. Barentsz’s ultimate goal is for MRI standard practice in men with elevated PSA, and global approval of Combidex. International physicians visit his center to learn his techniques and implement them themselves.
The research in Boutros’ laboratory lies at the intersection of clinical, molecular and imaging data. He focuses on how these diverse pieces of information can be linked to personalize therapy for cancer patients. By applying techniques from modern data science strategies, particularly machine-learning, he creates biomarkers to help ensure therapies are selected that maximize cure and minimize morbidities. His work sometimes centers on specific tumor types, particularly prostate and thyroid, and often includes others in conjunction to identify general and tumor-type specific features of cancer.
Mathieu Burtnyk is the Vice President of Clinical Affairs at Profound Medical, manufacturer of the TULSA system for MRI-guided transurethral ultrasound ablation of prostate tissue. He has worked with therapeutic ultrasound and imaging technologies for prostate for over a 15 years, starting his career in academia and obtaining his PhD in Medical Biophysics at the University of Toronto and Sunnybrook Health Sciences Center.
Dr. Carlsson is an Assistant Attending Epidemiologist at MSK with 14 years of prostate cancer research experience and over 100 scientific publications. Her PhD thesis stemmed from the world’s largest study of prostate cancer screening, the European Randomized Study of Screening for Prostate Cancer (ERSPC). Currently, Dr. Carlsson’s research focuses on developing risk-stratified approaches to screening, diagnosis, treatment, and follow-up of prostate cancer patients. She is also the PI of two studies funded by the Patty Brisben Foundation to improve methods for asking questions about women’s sexual health to be inclusive of all sectors of the community.
Dr. Cooperberg graduated from Dartmouth College and received his MD and MPH from Yale University. He trained in General Surgery and Urology and completed a fellowship in Urologic Oncology, both at UCSF. He is part of the multidisciplinary urologic oncology team of the Helen Diller Family Comprehensive Cancer Center, and also maintains privileges at San Francisco General Hospital. Cooperberg was awarded the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award and was also named Young Urologist of the Year.
Dr. Crawford received his MD from the University of Cincinnati and he completed his postgraduate internship and residency in Urology at the Good Samaritan Hospital (Cincinnati). He was awarded a Genitourinary Cancer fellowship at the University of California Medical Center in Los Angeles. He has authored or co-authored 400+ articles, which have been published in journals including Urology, The New England Journal of Medicine (NEJM), and the Journal of the National Cancer Institute. He has published five textbooks. He is an editorial reviewer or consultant for publications including Urology, Journal of Urology, NEJM, Cancer, and the Journal of Clinical Oncology.
Dr. Efstathiou received his MD from Harvard Medical School and PhD from University of Oxford, and completed his residency in the Harvard Radiation Oncology Program. His research has informed clinical guidelines and focuses on the effectiveness of advanced/emerging therapies including proton beam, the adverse effects of hormonal therapy, improving radiation therapy for testicular cancer, and long-term outcomes of bladder-sparing chemoradiation. He holds leadership positions in cooperative groups (NRG), professional societies (ASTRO), and National Cancer Institute. Other projects include the development of web-based patient decision aids/support tools, evaluating the multidisciplinary approach to cancer care, and global oncology outreach efforts with Botswana.
Dr. Feldman’s research focuses on translational and clinical research in prostate, kidney, and bladder cancers. He has received a Prostate Cancer Foundation Young Investigator Award and has been awarded a Physician Research Training Award by the Department of Defense. He is a co-PI on a DoD award developing conditionally-reprogrammed cells, and is a co-investigator on an NIH RO1 on metabolomic imaging in prostate cancer. In addition, he has worked to develop clinical databases in active surveillance in prostate cancer, use of imaging and fusion biopsy in prostate cancer, surgical and ablative treatments for renal cell carcinoma, and renal mass biopsy.
Dr. Feller graduated from the Ohio State University School of Medicine, completed postgraduate training at Stanford University, and is board-certified in Diagnostic Radiology. He served in the Air Force as Chief of MRI, David Grant Medical Center. He was previously Assistant Clinical Professor, Stanford Department of Radiology, where he was awarded the Volunteer Clinical Faculty Teacher of the Year. He has given 400+ lectures worldwide, co-authored numerous peer-reviewed articles and book chapters, and is editor of the textbook Shoulder Magnetic Resonance Imaging. Dr. Feller leads an MRI-based prostate cancer detection and treatment program at Desert Medical Imaging, providing care to 3,000+ men.
Dr. Fennessy is an MD BCh, PhD with significant clinical expertise in imaging in oncology. She is the Program Director of the Cancer Imaging fellowship Program at Dana-Farber Cancer Institute and co-PI of the T32 training grant: “Training in Image Guidance, Precision Diagnosis and Therapy” at Brigham and Women’s Hospital. She has extensive research interest and experience in quantitative MR imaging of prostate cancer, specifically in assessment of repeatability of prostate MRI, in determining the optimal histopathology correlative processes for prostate MR validation, and in the use of MRI for assessing response to therapy for prostate cancer.
Jurgen Fütterer focuses on image-guided interventions and robotics in cancer, with a special focus on MR-guided interventions, such as MR-guided cryosurgery, focal laser ablation, and focused ultrasound surgery. Dr. Fütterer qualified at Radboud University Nijmegen and completed his PhD on MRI techniques in localizing and staging of prostate cancer. He was a radiology resident at the University Medical Centre, Nijmegen, and a fellow in interventional radiology/body MRI in 2009. Dr. Fütterer has published extensively on MRI in prostate cancer, and introduced a robotic device for MRI-guided biopsy of the prostate, which has been established as a novel prostate intervention.
Dr. Sangeet Ghai is the Deputy Chief (Research) and Associate Professor in the Joint Department of Medical Imaging (JDMI) University of Toronto, Canada. He is also the director of Prostate Center. His main areas of interest and research include Prostate imaging and intervention. He is actively involved in Prostate MRI techniques, High resolution ultrasound imaging of Prostate, and In-bore focal treatment for intermediate risk Prostate Cancer – MR guided focused ultrasound surgery and MR guided focal laser ablation.
Dr. Haider received his MD from University of Ottawa and undertook additional training at University of Toronto and Cleveland Clinic Foundation. Dr. Haider focuses on prostate cancer localization with MRI using multiparametric approaches; radiological pathologic correlation in prostate cancer, GU malignancies and other abdominal and pelvic malignancies; and feature analysis of tumors for imaging biomarker validation and therapy response assessment. He has worked on establishing guidelines for the use of mpMRI for prostate cancer including the Pi-Rads standard for performance and interpretation of prostate mpMRI. Dr. Haider holds three patents on medical imaging technologies and has 180+ publications in peer-reviewed journals.
As director of the Jefferson Prostate Diagnostic Center – a collaboration among the departments of urology, radiology and pathology – Dr. Halpern has been actively exploring the application of contrast-enhanced ultrasound (CEUS) to the diagnosis of prostate cancer (PCa). Several clinical trials at Jefferson have demonstrated improved detection of PCa based upon CEUS targeted biopsy. Recent studies have employed newer ultrasound techniques, including flash replenishment and subharmonic imaging to improve the detection of neovascularity associated with PCa. A recent study has demonstrated the utility of CEUS to detect significant PCa that was missed by multi-parametric MRI.
Dr. Mukesh Harisinghani serves as Director of the Clinical Discovery Program Center for Molecular Imaging Research at Massachusetts General Hospital and is the Section Editor for GU Radiology for the American Journal of Roentgenology (AJR). Dr Harisinghani has been practicing in the field of abdominal radiology for over 20 years, has published over 150 peer reviewed papers, and has edited 5 textbooks in the field of Radiology.
Dr. Hope received his MD from Stanford University and completed an internship at Kaiser Permanente, residency in Diagnostic Radiology at UCSF, and clinical fellowship in Body MRI and Nuclear Medicine at Stanford. He is the Director for Molecular Therapy. Hope is the PI on the Ga-68 PSMA-11 IND, has helped lead the development of the clinical PET/MRI program, and is developing the program for neuroendocrine tumors at UCSF. He has published 100+ peer-reviewed articles and is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, and International Society for Magnetic Resonance in Medicine.
Dr. Hu is a urologic oncologist specializing in image-guided diagnosis and treatment of prostate cancer. He previously served as Director of Robotic and Minimally Invasive Surgery at Brigham and Women’s Hospital/Harvard Medical School. He was recruited to UCLA where he trained as the Henry Singleton Chair of Robotic and Minimally Invasive Surgery and later joined the faculty at Weill Cornell Medical College as the Director of the LeFrak Center for Robotic Surgery and the Ronald P. Lynch Chair in Urologic Oncology. His comparative effectiveness research interests have been funded by federal and foundation sources. He has authored 240+ peer-reviewed papers.
Dr. Iagaru completed medical school at Carol Davila University of Medicine (Romania) and an internship at Drexel University. He began his residency at University of Southern California Keck School of Medicine in the Division of Nuclear Medicine (where he was chief resident), and finished his residency and a PET/CT fellowship at Stanford University in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; and targeted radionuclide therapy. He has published 140+ papers in peer-reviewed journals, alongside seven book chapters and one book.
Dr. Jani is a radiation oncologist at Emory University with an interest in prostate cancer; particularly, in imaging as it relates to prostate cancer radiotherapy. He is involved in cooperative group trials and investigator initiated trials related to novel molecular imaging and quantitative ultrasound. He also has several research grants in this arena, including from the NIH R01 and DOD PCRP mechanisms.
Dr. Kibel’s research interests include performing whole exome sequencing on germline DNA to determine if rare variants are associated with risk of aggressive disease and integrating environmental risk determinants to potentially alter genetic predisposition to disease. Dr. Kibel lead efforts to integrate improved imaging into patient care, including C11 Acetate PET in prostate cancer. He is actively involved in trials integrating adjuvant and neoadjuvant systemic therapy into management of patients with urologic malignancies. Dr. Kibel also has a practice focusing on complex open and minimally invasive oncology cases and robotic surgery for urologic cancers.
Dr. Klein graduated cum laude from the University of Pittsburgh School of Medicine and completed residency training in Urology at the Cleveland Clinic and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. His research covers all stages of prostate cancer, focusing on genomics and clinical trials, and he has served as National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial. He has published 600+ papers, authored/edited 8 books, and serves as the Editor-in-Chief of Urology. Dr. Klein is part of numerous professional societies and scientific advisory boards and has delivered 200+ lectures globally.
Dr. Koo was previously Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. He completed his transitional internship and radiology residency at the University of Pennsylvania and fellowship at Harvard. Dr. Koo serves on the Radiological Society of North America’s scientific program committee, the ABR’s nuclear radiology certifying exam committee, and is Chair of the Quality and Evidence Committee of the Society of Nuclear Medicine and Molecular Imaging. Dr. Koo has published in journals including Radiology, European Journal of Nuclear Medicine and Molecular Imaging, and Journal of the American College of Radiology.
Daniel Margolis is a graduate of UC, Berkeley and earned his M.D. from USC (California). After a transitional year internship at Los Angeles VA Healthcare System, he completed a residency in Diagnostic Radiology at UCLA. Dr. Margolis completed a fellowship in Advanced Imaging at Stanford University Medical Center and the K30 Graduate Training Program in Translational Investigation at UCLA. He has 90+ publications regarding using MRI for detecting and characterizing prostate cancer. He serves on the American College of Radiology Prostate Imaging Reporting and Data Systems committee and is co-chair of the Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel.
Dr. Moses graduated Phi Beta Kappa from Morehouse College, received his MD and PhD from Baylor College of Medicine, completed his General Surgery internship and Urology training at Emory, and completed a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, where he served as Chief Administrative Fellow. His clinical practice focuses on advanced prostate cancer, including clinical trials, as well as surgical management of several cancers. His research focuses on health disparities in urologic cancers, the role of health literacy in patient interactions with the health care system, and optimal care for patients with metastatic and/or castrate-resistant prostate cancer.
Dr. Nanus completed his medical training at Albert Einstein College of Medicine, fellowship in medical oncology at Memorial Sloan Kettering Cancer Center, and research training at the Sloan Kettering Institute. He was a physician scientist at MSKCC and later joined the full-time faculty of Weill-Cornell Medicine, where he served as Chief of the Division of Hematology and Medical Oncology. He serves as PI in clinical, translational, and basic research in genitourinary malignancies and novel targeted therapies, and has 200+ publications. He has received numerous awards, including membership in the American Society for Clinical Investigation and the Association of American Physicians.
Dr. Oto’s research interest focus is the development and clinical application of novel prostate MRI acquisition and interpretation and of minimally-invasive image-guided therapy. His research has resulted in 200+ publications and 150+ scientific exhibits at national and international meetings. His group has developed new MR sequences, piloted CAD software for prostate MRI, and tested MR-guided therapy methods including laser and focused ultrasound ablation. He has several industry, foundation and NIH grants; serves at the Editorial Board of Radiology; and has received numerous awards including Distinguished Investigator Award, RSNA honored educator award and Distinguished Senior Clinician Award.
Dr. Pollack’s research interests center on the therapeutic management of prostate cancer, with an emphasis on applying biomarkers, including quantitative imaging, tissue genomic, and liquid biopsy markers to predict risk. Dr. Pollack co-leads the NCI consortium on imaging and biomarkers and the genitourinary translational research program in the NRG cooperative group. A key emphasis of ongoing trials and his laboratory is the integration of quantitative mpMRI to better risk classify habitats in the prostate, assess tumor heterogeneity, direct prostate biopsies, and target radiotherapy delivery. Dr. Pollack received his MD and his PhD from the University of Miami.
Dr. Punnen completed his medical school at Queen’s University and Urology Residency at the University of Toronto in Canada. He then completed a uro-oncology fellowship and Master’s in Clinical Research at the University of California, San Francisco. He is board certified in both urology and uro-oncology. His primary research interest is in localized prostate cancer. Specifically, his work has evaluated imaging, molecular, and genomic markers that play a role in prostate cancer diagnosis and prognosis. He also does outcomes and health service research on trends in the incidence and management of prostate cancer.
Dr. Raman is an expert in Abdominal and Pelvic imaging (CT, MRI, US and X-Ray) and interventional radiology (image guided procedures), especially in the area of tumor ablation and Fibroid Treatment. He is director of the Abdominal Imaging Fellowship at UCLA, and co-director of the Fibroid Treatment Program at UCLA. Dr. Raman received his MD from the University of South California Keck School of Medicine and completed a fellowship in Radiological Sciences at the University of California San Diego and a residency in Radiological Sciences at the University of California Los Angeles. He is board-certified in Diagnostic Radiology
Dr. Rastinehad was dual fellowship-trained in the Urologic Oncology and Image Guided Urology Fellowships at the NIH. He is currently developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety, as well as evaluating prostate embolization in lieu of transurethral resection of the prostate. He served as the course director for the first international course on MR US fusion guided prostate biopsies sponsored by the AUA. Dr. Rastinehad has published 75+ articles, authored multiple text book chapters, and was the senior editor of Interventional Urology.
Dr. Rider’s research interests include the role of modifiable lifestyle factors in prostate cancer development and progression; the identification of tumor biomarkers to improve disease management; and methodological challenges in the development of novel prostate cancer therapies, including the evaluation of surrogate endpoints. She collaborates on several studies based in Sweden, including the landmark SPCG-4 trial, and on established US-based cohort studies such as the Health Professionals Follow-up Study and Southern Community Cohort Study.
Mack Roach III is Professor of Radiation Oncology and Urology and formerly Chair of the Department of Radiation Oncology at University of California San Francisco. He obtained his medical degree from Stanford University and has focused on the use of various forms of radiation in the management of prostate cancer. He has published 300+ Peer-reviewed publications, Book Chapters and Editorials. Professor Roach chaired two large prospective phase III randomised trials (RTOG 9413 and RTOG 0924), including >3500 men with clinically localized prostate cancer. Professor Roach currently serves on the NCI National Cancer Advisory Board (appointed by President Obama in 2012-present).
Dr. Ross is an urologist and physician scientist with a clinical focus in prostate cancer. He is part of Texas Oncology and Texas Urology Specialists, serves as the Executive Medical Director of the Mary Crowley Cancer Research Center in Dallas, and is an associate chair for the US Oncology Research genito-urinary committee. Previously, Dr. Ross directed the Brady Urological Prostate Cancer Program of the Johns Hopkins School of Medicine. Dr. Ross has led research efforts in basic science, translational, and clinical areas of prostate cancer research and has 100+ peer-reviewed articles published as well as several editorials and book chapters.
Steven Rowe clinically practices both diagnostic radiology and nuclear medicine and his research work focuses on applications of novel molecular imaging agents for positron emission tomography (PET) and single-photon emission computed tomography (SPECT). In particular, his interests include the use of prostate-specific membrane antigen (PSMA)-targeted PET agents in prostate cancer and renal cell carcinoma, as well as the clinical utilization of 99mTc-sestamibi SPECT for non-invasive characterization of renal masses. He and his colleagues recently developed and validated a structured reporting system for delineating and codifying findings on PSMA PET known as PSMA reporting and data system (PSMA-RADS).
Dr. Sant completed his MD at Dublin University, general surgery residency at Albert Einstein College of Medicine, and urology residency at Tufts University. He holds an FRCS from Royal College of Surgeons. He has served in academic committee leadership positions with the NIH, AUA, and the ABU Examination Committee. Dr. Sant developed the first patient reported outcomes instrument for interstitial cystitis and has published 128 peer-reviewed articles, 36 book chapters, two textbooks and ten Urology Journal Supplement Editorship. He launched four urology products – Taxotere, Jevtana, Eligard, and Uroxatral – and two rare diseases products, Lumizyme and Kynamro.
Dr. Amita Shukla-Dave was recently named the Fellow International Society for Magnetic Resonance in Medicine (ISMRM), May 2019, for her work in developing and standardizing clinically relevant quantitative imaging methods and identifying novel biomarkers for oncological applications. She is an active member of the Radiological Society of North America/ Quantitative Imaging Biomarkers Alliance (QIBA); Co-Chairman for MRI working group NCI/Quantitative Imaging Network (QIN); member of American Association of Physicists in Medicine’s Imaging Metrology and Standards Subcommittee (MSSC); and member of Quantitative MR study group /ISMRM.
Dr. Sidana is an Assistant Professor and the Director of Urologic Oncology in the Division of Urology at the University of Cincinnati Medical Center, Cincinnati, OH. His clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers. His research interests include functional prostate imaging, image-guided and focal treatments for prostate cancer and clinical trials on novel treatments for urologic cancers.
Mohummad Minhaj Siddiqui completed training at MIT, Harvard, and the NIH in the field of Urology and subspecialty of Urologic Oncology. He is Director of Urologic Oncology at the Greenebaum Comprehensive Cancer Center at University of Maryland Medical System. His research interests are in the areas of cancer metabolism and how better understanding of metabolic derangements in cancer can lead to improved diagnosis and treatment. Clinically, he is particularly interested understanding improved integration and utilization of MRI for the diagnosis and management of prostate cancer.
Dr. Sokoloff is an expert in the surgical management of urologic cancer. As a translational surgeon-scientist he has advanced the understanding and treatment of these cancers. He is also a leading advocate for improved access and education for underserved at-risk populations. Dr. Sokoloff earned his MD from Stanford University and completed surgery and urology residencies at UCLA followed by a fellowship in molecular urology and therapeutics at the University of Virginia under the mentorship of Dr. Leland Chung. Since then Dr. Sokoloff has held leadership positions at the University of Chicago, OHSU, University of Arizona, and the University of Massachusetts.
Ben Solomon is a board-certified pediatric geneticist who focuses on using genetics and genomics to identify, understand and care for patients with rare and common genetic conditions, alongside broad applications of genomic medicine. Solomon has authored 100+ peer-reviewed articles, book chapters, and textbooks, and is an active lecturer and educator. Dr. Solomon completed his residency and fellowship at the National Human Genome Research Institute at the NIH and at Children’s National Medical Center, and served as Chief, Division of Medical Genomics, Inova Translational Medicine Institute. Ben is now the head of GeneDx, a large genetics and genomics laboratory.
Dr. Song serves as the Co-Director of the Prostate Multidisciplinary Clinic as well as Associate Professor in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University School of Medicine. His research focus is on the technological innovations for improving the practice of prostate brachytherapy, as well as the conduct of clinical trials in innovative methods of radiotherapy for prostate cancer and other genitourinary malignancies. He performed some of the original research testing the feasibility of hydrogel spacers and establishing their benefit in reducing dose to the rectum.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device; he is also a pioneer in focal therapy. In his practice, Dr. Sprenkle believes in working with patients to come up with individualized treatment plans to minimize the impact of prostate cancer diagnosis and treatment on a their health and quality of life.
Dr. Stoyanova has extensive background in approaches for utilization of imaging techniques in cancer research, diagnosis and treatment, as well as in developing methods for the analysis, mining, and interpretation of “big data”: genomics, metabolomics, and radiomics. In prostate cancer, Dr. Stoyanova’s overarching goal is to develop a multifaceted approach, whereby combining data about biopsy location, biopsy content, and in vivo imaging (functional and metabolic) can lead to the informed design of effective treatment.
Dr. Sweeney is a Medical Oncologist at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He received his medical degree from the University of Adelaide (Australia) and completed an internship at the Royal Adelaide Hospital (Australia). Dr. Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center (WI, USA) and a fellowship and faculty in hematology/oncology at Indiana University Medical Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School in 2009. His primary research interest is drug discovery and development, focusing on prostate and testicular cancer.
Dr. Verma completed a diagnostic radiology residency at the University of Cincinnati and a fellowship in Abdominal Imaging from the Johns Hopkins Medical Center. Dr. Verma’s clinical expertise and current clinical research interests are in genitourinary MR imaging. She has published extensively and delivered numerous invited lectures on the topic of prostate MRI and MR-Guided Interventional Procedures.
Dr. Vickers’ research falls into three broad areas: randomized trials, surgical outcomes research and molecular marker studies. A particular focus of his work is the detection and initial treatment of prostate cancer. Dr. Vickers has analyzed the ‘learning curve’ for radical prostatectomy. He is working on a series of studies demonstrating that a single measure of prostate specific antigen (PSA) taken in middle age can predict lethal prostate cancer up to 30 years subsequently. He has also developed a statistical model to predict the result of prostate biopsy, work that has been commercialized and is clinically available through Opko Diagnostics.
Dr. Weber graduated from and trained at TUM. He has been Associate Professor, Department of Molecular and Medical Pharmacology, UCLA; Professor and Chair, Department of Nuclear Medicine, University of Freiburg; Chief of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center; and Professor of Radiology at Weill-Cornell Medical College. He focuses on molecular imaging of cancer for therapeutic interventions, and is interested in targeted radionuclide therapy and theranostics. Dr. Weber has published 250+ papers in, and served on editorial boards of, journals including the Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Journal of Clinical Oncology, and others.
Dr. Liang WANG is a full professor and attending radiologist in Tongji University Hospital, Wuhan, China. He received his training in Rotterdam University and Memorial Sloan-Kettering Cancer Center under the mentorship of Dr. Hedvig Hricak and Dr. Gabriel P. Krestin. Dr. Wang has made a significant impact on the advancement of prostate cancer diagnosis, which as been instrumental for saving many lives in China. Dr. Wang has a strong interest in prostate MRI and related spectroscopic imaging.
Dr. Weinreb has spent three decades developing and refining clinical applications of prostate MRI. He was Principal Investigator for the NCI sponsored cooperative study ACRIN 6659: Multicenter Study of In Vivo MR Spectroscopy for the Evaluation of Prostate Cancer and served as Co-Chair or the PI-RADS Steering Committee from 2011-2019, which produced Pi-RADS v2.0 and v2.1. He is currently Chair of the ACR Advanced Prostate Imaging and Targeted Therapy Committee.
Dr. Wheeler received his MD with high honors from Baylor College of Medicine and completed his residency in Anatomic and Clinical Pathology at BCM, and is also board-certified in Cytopathology. He has served on the faculty at Baylor for 38, and as chair of the Department of Pathology & Immunology at BCM for almost 15, years. He served for six years on the governing board of the College of American Pathologists where he was chair of their Council on Scientific Affairs. Dr. Wheeler has garnered an international reputation in clinical research with 300+ peer-reviewed publications regarding prostate cancer.
Dr. Zappala graduated from the University Of Massachusetts Medical School,University Of Massachusetts Medical School in 1983. Dr. Zappala works in Salem, NH and 1 other location and specializes in Urology. Dr. Zappala is affiliated with Holy Family Hospital and Lahey Medical Center Peabody
Dr. Wibmer is a board-certified Assistant Attending Radiologist at Memorial Sloan Kettering Cancer Center with sub-specialization training in oncologic body and molecular imaging. While his clinical experience includes interpretation of CT, MRI, PET/CT, and PET/MRI studies, he has developed a special scientific interest in imaging of primary and metastatic prostate cancer. The overarching goal of his research is the development of anatomic and molecular imaging techniques into prognostic and predictive biomarkers by studying the association of a cancer’s imaging phenotype with clinically relevant outcome data, always in conjunction with clinical, histopathologic, and molecular biomarkers.
Dr. Zelefsky received his MD from Albert Einstein College of Medicine and completed his Residency in Radiation Oncology at MSKCC. As Chief of the Brachytherapy Service, he has significant expertise using high-dose-rate and low date rate brachytherapy for patients with localized and advanced or aggressive prostate cancer, as well as for recurrent tumors post-external-beam radiation. He has also developed the image-guided stereotactic radiosurgery program for prostate cancer at MSKCC and was the pioneer of the use of IMRT and IGRT for treating men with prostate cancer. Dr. Zelefsky is Editor-in-Chief of Brachytherapy and past president of the American Brachytherapy Society.